Reducing Pancreatic Cancer Disparities Through the NCI Community Oncology Research Program (NCORP) (Part 1/2)
In short
The NCI Community Oncology Research Program (NCORP) brings cancer clinical trials directly into local communities across the U.S., helping to reduce the gap in survival outcomes between rural and urban patients. The program pays special attention to underserved groups — including racial and ethnic minorities, rural residents, and others who have historically had less access to quality cancer care — and has a specific focus on pancreatic cancer early detection, including a large study exploring the link between new-onset diabetes and pancreatic cancer.
- •Ask your local oncologist whether your community has an NCORP site nearby — participating in a clinical trial close to home means staying near your support system while getting guideline-driven care.
- •If you or a family member has been recently diagnosed with diabetes, ask your doctor about the New Onset Diabetes Cohort study, which is actively enrolling 4,000 patients to look for early signs of pancreatic cancer.
- •Clinical trial participation has been shown to reduce survival differences between rural and urban patients, so joining a trial may be worth discussing even if you don't live near a major cancer center.
- •NCORP sites like John H. Stroger Jr. Hospital in Chicago prioritize enrolling patients from minority and lower-income communities — if you've felt overlooked by research before, these sites are specifically designed with your population in mind.
Ask anything about this — free, no signup
Instant answers grounded in real guidelines, not the internet.
NCORP Whether you live in the heart of a major city or in a remote rural community, Dr. Worta McCaskill-Stevens is determined that you will have access to quality cancer care. As Director of the NCI Community Oncology Research Program (NCORP), the medical oncologist has reason to be hopeful.
The national network of investigators, cancer care providers, academic institutions, and other organizations has successfully enrolled thousands of patients from diverse communities across the United States in multi-site clinical trials since its formation in 2014.
This is important because, according to a 2018 study in the Journal of the American Medical Association (JAMA), the differences in survival rates between rural and urban patients are significantly reduced when patients are enrolled in a cancer clinical trial. D. , a health services researcher and biostatistician at the Fred Hutchinson Cancer Research Center , Seattle, Washington, who led the NCORP-funded study.
" A Corps of Cancer Care Delivery Cancer clinical research has traditionally been conducted at academic medical centers, but most cancer care actually takes place in the community setting. Being able to join research studies in a person’s own community allows the person to stay close to family, friends, support systems, and their local physicians and health organizations, explains McCaskill-Stevens.
“Expanding clinical research beyond the academic environment allows access to a larger and more diverse patient population in a variety of ‘real world’ healthcare settings,” she adds. ” Engaging community oncologists in collaborative research can also facilitate the uptake of effective, evidence-based practices into routine care, McCaskill-Stevens notes.
NCORP includes seven research bases, which serve as hubs to design and conduct multi-center clinical trials and cancer care delivery research studies, and 46 community sites to accrue study participants and engage community partners. At NCORP’s most recent annual meeting , in September 2018, McCaskill-Stevens reported that the growing program now has 960 component and subcomponent sites.
, (at the time of this story) appreciates the work NCORP has done to bring clinical trials and care to communities across the country, and has committed to an increase in NCORP funding. “NCORP is a way whereby we can provide great care and clinical research to patients we wouldn’t be able to reach otherwise,” Sharpless said at the meeting.
Equality Instead of Cancer Disparities One of the core missions of NCORP is to address and reduce cancer disparities—cancer-related problems that disproportionately affect racial/ethnic minorities and underserved populations. To help accomplish this, the program has 12 specially designated minority/underserved community sites in areas with patient populations comprising at least 30 percent racial/ethnic minorities or rural residents.
One of these sites is the John H. Stroger, Jr. Hospital of Cook County . Located in the Illinois Medical District on Chicago's Near West Side, the hospital is the largest component of the safety net for healthcare in Chicago and suburban Cook County.
Its participation in the network has been a resounding success, recruiting more than 1,715 patients to clinical trials, and publishing several studies in peer-reviewed academic journals and conferences. “Our mission is to address the shortage of accessible cancer healthcare resources for Chicago's poor and minority families,” says site director Thomas E. D.
” Education and outreach are also important activities at the site, as well as the program as a whole. In addition to clinical studies, NCORP’s social scientists also examine how financing systems, organizational structures/processes, health technologies, and healthcare provider and individual behaviors affect cancer outcomes, access to and quality of care, cancer care costs, and the health and well-being of cancer patients and survivors. D.
, NCORP’s lead scientist for its Healthcare Delivery Research program, explains that understanding and addressing health disparities will continue to be a focus over the next couple of years. Populations of specific interest include adolescents and young adults, the elderly, racial and ethnic minorities, sexual and gender minorities, and rural residents.
As she reported at the group’s annual meeting , pancreatic cancer will be a particular focus in 2019. In order to investigate the link between new-onset diabetes and pancreatic cancer , NCORP is helping to enroll 4,000 patients to the New Onset Diabetes Cohort study .
The goals of the study—which is also backed by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) and the Pancreatic Cancer Detection Consortium (PCDC)—are to identify and follow a large cohort; develop a biorepository; clinically validate promising biomarkers of pancreatic ductal adenocarcinoma (PDAC); and develop an early detection protocol for sporadic PDAC.
Highlights
from ASCO GI 2026 Survivor Stories January 28, 2026 • 3 Min Catching It Early and Moving Fast Managing Your Care January 22, 2026 • 3 Min PancChat Gets a New Home: A Podcast You Can Press “Play” On Ask the Doctor If you are in long-term treatment or have completed treatment, you may have concerns about what is next. Here are some questions to ask your doctor.
Related pancreatic questions
- →Need recommendations for pancreatic cancer stage 4 that has spread to the liver. What treatment options are available
- →What are the must haves for someone soon to be receiving chemo by port for next 3 months, then followed by surgery?...
- →What is the real-world experience with daraxonrasib for metastatic pancreatic cancer, and how do patients tolerate it
- →What are the treatment options for Pancreatic Cancer
- →Which biomarker tests (KRAS, BRCA1/2) are recommended for my Pancreatic Cancer, and how will the results guide my...
- →What fertility preservation options exist before Pancreatic Cancer treatment in young adults
- →What is a multidisciplinary tumor board and should my Pancreatic Cancer case be presented
- →What is the 5-year survival rate for pancreatic cancer
Want to learn more about your specific case?
Upload your medical records and ask Navis questions tailored to your diagnosis.